Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey - Scorecard - MDSpire
Advertisement
Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey
Clinical Scorecard: Overview of Neuro-Oncological Molecular Tumor Boards in Germany: Insights from a Nationwide Follow-Up Survey
At a Glance
Category
Detail
Condition
Primary brain tumors, especially gliomas
Key Mechanisms
Molecular tumor profiling to guide personalized treatment decisions via Molecular Tumor Boards (MTBs)
Target Population
Neuro-oncology patients with brain tumors, particularly gliomas
Care Setting
University hospitals, affiliated teaching hospitals, outpatient specialty centers in Germany
Key Highlights
MTBs are widely implemented across German neuro-oncology centers with nearly universal access.
Significant heterogeneity exists in MTB structure, tumor inclusion criteria, recommendation practices, and implementation.
Recent advances include the INDIGO trial showing benefit of Vorasidenib for IDH-mutant gliomas and updated EANO and ESMO guidelines standardizing molecular testing and MTB quality.
Guideline-Based Recommendations
Diagnosis
Perform structured molecular testing in gliomas based on EANO 2023 guidelines defining clinically relevant biomarkers.
Management
Utilize MTBs to interpret complex genomic data and guide individualized treatment decisions.
Consider targeted therapies such as IDH1/2 inhibitors (e.g., Vorasidenib) for eligible patients.
Monitoring & Follow-up
Implement follow-up mechanisms and standardized reporting as recommended by ESMO consensus quality indicators for MTBs.
Risks
Limited availability of effective targeted therapies for brain tumors.
Barriers including lack of reimbursement for off-label therapies and inconsistent insurance coverage.
Variable integration of MTB decisions into clinical workflows.
Patient & Prescribing Data
Patients with neuro-oncological tumors, primarily gliomas, discussed in MTBs across German centers.
Targeted therapies show promise (e.g., Vorasidenib for IDH-mutant gliomas), but implementation is challenged by reimbursement issues and limited trial access.
Clinical Best Practices
Establish in-house MTBs or referral pathways to external MTBs for molecular case review.
Develop and use standardized referral systems (e.g., SOPs) for MTB patient assignment.
Incorporate multidisciplinary teams including neurosurgery, neurology, radiation oncology, neuropathology, and medical oncology in MTB discussions.
Adopt digital tools such as structured databases, virtual tumor boards, and AI support to enhance MTB workflows.
Align MTB practices with international quality frameworks (e.g., ESMO indicators) to improve standardization and follow-up.
